Table 5 Prevalence of glucose homeostasis abnormalities according to lipodystrophy defined clinically and by FMR
Lipodystrophy defined clinically | Lipodystrophy defined by FMR | ||||||
|---|---|---|---|---|---|---|---|
Total (n = 228) | Without CL (n = 89) | With CL (n = 129) | P | Without L (n = 100) | With L (n = 70) | P | |
NG [n (%)] | 117 (49.1) | 44 (49.4) | 63 (48.8) | 0.364 | 62 (62.0) | 29 (41.4) | 0.021 |
IFG [n (%)] | 18 (8.3) | 10 (11.2) | 8 (6.2) | 5 (5.0) | 11 (15.7) | ||
IGT [n (%)] | 49 (22.5) | 21 (23.6) | 28 (21.7) | 19 (19.0) | 15 (21.4) | ||
DM [n (%)] | 44 (20.2) | 14 (15.7) | 30 (23.3) | 14 (14.0) | 15 (21.4) | ||